Suppr超能文献

共晶溶解度优势图作为控制溶解、过饱和和沉淀的手段。

Cocrystal Solubility Advantage Diagrams as a Means to Control Dissolution, Supersaturation, and Precipitation.

机构信息

School of Chemical Engineering and Technology, Key Laboratory for Modern Drug Delivery and High Efficiency , Tianjin University , Tianjin 300072 , People's Republic of China.

Department of Pharmaceutical Sciences, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109-1065 , United States.

出版信息

Mol Pharm. 2019 Sep 3;16(9):3887-3895. doi: 10.1021/acs.molpharmaceut.9b00501. Epub 2019 Jul 31.

Abstract

Cocrystals are often more soluble than needed and pose unnecessary risks for precipitation of less soluble forms of the drug during processing and dissolution. Such conversions lead to erratic cocrystal behavior and nullify the cocrystal solubility advantage over parent drug (SA = /). This work demonstrates a quantitative method for additive selection to control cocrystal disproportionation based on cocrystal solubility advantage (SA) diagrams. The tunability of cocrystal SA is dependent on the selective drug-solubilizing power of surfactants (SP = (/)). This cocrystal property is used to generate SA-SP diagrams that facilitate surfactant selection and provide a framework for evaluating how SA influences drug concentration-time profiles associated with cocrystal dissolution, drug supersaturation, and precipitation (DSP). Experimental results with indomethacin-saccharin cocrystal and surfactants (sodium lauryl sulfate, Brij, and Myrj) demonstrate the log-linear relationship characteristic of SA-SP diagrams and the dependence of σ and dissolution area under the curve (AUC) on SA with characteristic maxima at a threshold supersaturation where drug nucleation occurs. This approach is expected to streamline cocrystal formulation as it facilitates additive selection by considering the interplay between thermodynamic (SA) and kinetic (DSP) processes.

摘要

共晶通常比需要的更易溶,并且在处理和溶解过程中会导致药物的溶解度较低的形式不必要地沉淀。这种转化导致共晶行为不稳定,并使共晶相对于母体药物的溶解度优势(SA=/)失效。这项工作展示了一种基于共晶溶解度优势(SA)图来控制共晶歧化的添加剂选择的定量方法。共晶 SA 的可调性取决于表面活性剂(SP=/)对药物的选择性增溶能力。该共晶性质用于生成 SA-SP 图,以促进表面活性剂的选择,并提供一个框架来评估 SA 如何影响与共晶溶解、药物过饱和和沉淀(DSP)相关的药物浓度-时间曲线。使用消炎痛-糖精共晶和表面活性剂(月桂酸钠、Brij 和 Myrj)的实验结果证明了 SA-SP 图的对数线性关系,以及 σ 和曲线下溶解面积(AUC)对 SA 的依赖性,在药物成核发生的阈值过饱和度处具有特征最大值。这种方法有望简化共晶配方,因为它通过考虑热力学(SA)和动力学(DSP)过程之间的相互作用来促进添加剂的选择。

相似文献

5
Mechanistic Basis of Cocrystal Dissolution Advantage.共晶溶解优势的机制基础。
J Pharm Sci. 2018 Jan;107(1):380-389. doi: 10.1016/j.xphs.2017.09.014. Epub 2017 Oct 6.
7
Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.理解共晶和盐在水溶液中溶解度的差异。
J Pharm Sci. 2018 Jan;107(1):113-120. doi: 10.1016/j.xphs.2017.10.033. Epub 2017 Oct 31.

引用本文的文献

本文引用的文献

2
Mechanistic Basis of Cocrystal Dissolution Advantage.共晶溶解优势的机制基础。
J Pharm Sci. 2018 Jan;107(1):380-389. doi: 10.1016/j.xphs.2017.09.014. Epub 2017 Oct 6.
7
Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5.共晶以促进超过5规则的难溶性化合物的递送。
Adv Drug Deliv Rev. 2016 Jun 1;101:143-166. doi: 10.1016/j.addr.2016.04.022. Epub 2016 Apr 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验